All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site

“How I treat” a patient with lower-risk MDS showing signs of ESA failure

Dec 14, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in lower-risk MDS.

Bookmark this article

During the MDS Hub Steering Committee meeting, held on October 26, 2023, Theo de Witte chaired a discussion on “How I treat” a patient with lower-risk myelodysplastic syndromes (MDS) showing signs of ESA failure, with contributions from Pierre Fenaux and Rafael Bejar.

How I treat” a patient with lower-risk MDS showing signs of ESA failure​

Theo de Witte discusses the optimal timing of erythropoiesis-stimulating agent (ESA) treatment in patients with lower-risk MDS and how to optimize treatment following ESA-treatment failure, including the use of luspatercept; he highlights results from the phase III MEDALIST (NCT02631070) and COMMANDS (NCT03682536) trials. The committee also discusses the assessment of quality of life in placebo-controlled studies and the use of luspatercept as a first-line therapy over ESAs, specifically in patients with MDS and SF3B1 mutations. They also raise the need to consider the side effects of luspatercept and the cost of treatment.

Related articles


Subscribe to get the best content related to MDS delivered to your inbox